X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SUN PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SUN PHARMA PIRAMAL ENTERPRISES/
SUN PHARMA
 
P/E (TTM) x 37.6 15.3 245.6% View Chart
P/BV x 3.7 3.6 104.1% View Chart
Dividend Yield % 0.6 0.2 304.8%  

Financials

 PIRAMAL ENTERPRISES   SUN PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-16
SUN PHARMA
Mar-16
PIRAMAL ENTERPRISES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0651,201 88.7%   
Low Rs805706 114.0%   
Sales per share (Unadj.) Rs383.0117.5 326.1%  
Earnings per share (Unadj.) Rs55.119.6 281.1%  
Cash flow per share (Unadj.) Rs74.123.8 311.1%  
Dividends per share (Unadj.) Rs17.501.00 1,750.0%  
Dividend yield (eoy) %1.90.1 1,784.7%  
Book value per share (Unadj.) Rs719.9130.5 551.7%  
Shares outstanding (eoy) m172.562,406.60 7.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.48.1 30.1%   
Avg P/E ratio x17.048.7 34.9%  
P/CF ratio (eoy) x12.640.1 31.5%  
Price / Book Value ratio x1.37.3 17.8%  
Dividend payout %31.85.1 622.5%   
Avg Mkt Cap Rs m161,3442,294,813 7.0%   
No. of employees `0003.814.7 25.7%   
Total wages/salary Rs m16,89847,971 35.2%   
Avg. sales/employee Rs Th17,472.619,169.8 91.1%   
Avg. wages/employee Rs Th4,466.93,253.0 137.3%   
Avg. net profit/employee Rs Th2,512.83,197.9 78.6%   
INCOME DATA
Net Sales Rs m66,099282,697 23.4%  
Other income Rs m2,4256,170 39.3%   
Total revenues Rs m68,524288,867 23.7%   
Gross profit Rs m18,72383,239 22.5%  
Depreciation Rs m3,27410,135 32.3%   
Interest Rs m9,3884,769 196.9%   
Profit before tax Rs m8,48574,505 11.4%   
Minority Interest Rs m3-11,126 -0.0%   
Prior Period Items Rs m1,593-19 -8,517.6%   
Extraordinary Inc (Exp) Rs m457-6,852 -6.7%   
Tax Rs m1,0329,349 11.0%   
Profit after tax Rs m9,50647,159 20.2%  
Gross profit margin %28.329.4 96.2%  
Effective tax rate %12.212.5 96.9%   
Net profit margin %14.416.7 86.2%  
BALANCE SHEET DATA
Current assets Rs m47,488308,646 15.4%   
Current liabilities Rs m104,362132,477 78.8%   
Net working cap to sales %-86.062.3 -138.1%  
Current ratio x0.52.3 19.5%  
Inventory Days Days4183 49.0%  
Debtors Days Days5188 58.3%  
Net fixed assets Rs m26,532133,606 19.9%   
Share capital Rs m3452,407 14.3%   
"Free" reserves Rs m114,024266,909 42.7%   
Net worth Rs m124,221314,042 39.6%   
Long term debt Rs m75,81231,167 243.2%   
Total assets Rs m308,356542,196 56.9%  
Interest coverage x1.916.6 11.5%   
Debt to equity ratio x0.60.1 614.9%  
Sales to assets ratio x0.20.5 41.1%   
Return on assets %6.19.6 64.0%  
Return on equity %7.715.0 51.0%  
Return on capital %10.017.8 56.1%  
Exports to sales %17.214.0 122.8%   
Imports to sales %6.63.1 210.1%   
Exports (fob) Rs m11,36239,572 28.7%   
Imports (cif) Rs m4,3648,882 49.1%   
Fx inflow Rs m14,43542,171 34.2%   
Fx outflow Rs m5,18321,583 24.0%   
Net fx Rs m9,25320,588 44.9%   
CASH FLOW
From Operations Rs m-67,77367,694 -100.1%  
From Investments Rs m-8,768-44,549 19.7%  
From Financial Activity Rs m76,199-19,243 -396.0%  
Net Cashflow Rs m-3423,902 -8.8%  

Share Holding

Indian Promoters % 52.9 63.7 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.1 78.0%  
FIIs % 26.6 23.0 115.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.3 198.8%  
Shareholders   93,274 133,026 70.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  SUVEN LIFE  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 18, 2017 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS